Comparison between Symbiotec Pharmalab IPO and Zepto IPO.
Symbiotec Pharmalab IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Zepto IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Symbiotec Pharmalab IPO is up to ₹2,180.00 Cr whereas the issue size of the Zepto IPO is up to ₹0.00 Cr. The final issue price of Symbiotec Pharmalab IPO is and of Zepto IPO is .
| Symbiotec Pharmalab IPO | Zepto IPO | |
|---|---|---|
| Face Value | ₹2 per share | |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹150.00 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹2,030.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 0 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹2,180.00 Cr | up to ₹0.00 Cr |
Symbiotec Pharmalab IPO opens on , while Zepto IPO opens on . The closing date of Symbiotec Pharmalab IPO and Zepto IPO is , and , respectively.
Symbiotec Pharmalab IPO P/E ratio is , as compared to Zepto IPO P/E ratio of .
| Symbiotec Pharmalab IPO | Zepto IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated Consolidated)Zepto Ltd.'s revenue increased by 99% and profit after tax (PAT) dropped by 26% between the financial year ending with March 31, 2026 and March 31, 2025.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 34.47 | 19.56 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 12.66 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 11.80 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹-16.60 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 11.79 | 165.89 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Symbiotec Pharmalab IPO Retail Individual Investors (RII) are offered 0 shares while in Zepto IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Symbiotec Pharmalab IPO and 0 shares in Zepto IPO.
| Symbiotec Pharmalab IPO | Zepto IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 0 shares | 0 shares |
| NII | 0 shares | 0 shares |
| RII | 0 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 0 shares |
Symbiotec Pharmalab IPO subscribed in total, whereas Zepto IPO subscribed .
